Sponsored

Radiopharm Theranostics (ASX:RAD) Expands US presence with Nasdaq Listing

November 27, 2024 01:23 PM AEDT | By Sonal Goyal
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • RAD’s American Depositary Shares (ADS) will start trading on Nasdaq under the ticker "RADX" on 27 November 2024 (U.S. time).
  • The Nasdaq listing complements the exiting US shareholders, who hold a 21% stake in the company.
  • RAD’s share price surged by 10.71% to AU$0.031 per share as of 27 November 2024

Radiopharm Theranostics (ASX:RAD) has announced that its American Depositary Shares (ADSs) will start trading on the Nasdaq Capital Market (Nasdaq) under the ticker symbol “RADX” on Wednesday, 27 November 2024, U.S. time. Each ADS represents 300 ordinary shares of Radiopharm.

The Nasdaq listing, which serves as a secondary listing alongside Radiopharm’s primary listing on the Australian Securities Exchange (ASX), is expected to enhance the company's presence in the U.S. market. Additionally, the listing complements the 21% stake held by US shareholders.

Notably, the listing was completed without raising additional capital in the US.

Initial trading volumes may be limited, as existing shareholders will need time to deposit their ordinary shares into the ADR (American Depositary Receipt) program to receive ADSs for Nasdaq trading.

Deutsche Bank Trust Company Americas has been appointed as the depositary, custodian, and registrar for the company’s ADR program.

The Nasdaq listing marks a significant milestone for Radiopharm Theranostics’ expansion into the US and international markets.

RAD shares surge

Following the update, RAD shares jumped 10.71% to AU$0.031 per share at the time of writing on 27 November 2024.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.